Navigation Links
Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange Exchange, proceeds with the development of its third drug CF502; this is in addition to CF101, which is currently in clinical trials and CF102, which is in preclinical phases. This weekend Can-Fite will present at the EUALR annual congress of rheumatology in-vitro and in vivo study results showing effective anti-inflammatory activity for CF502. The EUALR congress is highly regarded and attracts global leaders in the Rheumatology arena.

The chemical structure of CF502 differs from that of the Company's first two drugs CF101 and CF102, and is characterized by higher affinity and selectivity to the A3 adenosine receptor, which is targeted by the Can-Fite's drugs. The drug attacks inflammatory cells and leads to programmed cell death (apoptosis) and suppression of the inflammatory process. Can-Fite is using human cells to investigate the effects and mechanism of action of CF502. The Company is currently finalizing the development of CF502 synthesis process, before entering preclinical and clinical development phases.

Can-Fite will present at the rheumatology congress in-vitro data showing that CF502 specifically targets inflammatory cells and does not affect healthy cells, and will also present the drug's molecular mechanism of action. In addition in vivo data showing marked anti-inflammatory effects of CF502 will be reported. The Company will also present new data on the expression of A3 adenosine receptor in various autoimmune diseases. High expression of this receptor is directly correlated with response of inflammatory cells to this drug.

Prof. Pnina Fishman, CEO of Can-Fite: "I am pleased with the rapid progress in the CF502 development program and with the in-vitro and in vivo trial results showing impressive anti-inflammatory activity for this drug.
'"/>




Page: 1 2

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
5. CuraGen Presents Update on Clinical Development Program for Belinostat
6. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
9. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
10. Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR
11. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
Post Your Comments:
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... ,Since the first system was invented in ... and patient care. During the 1960s, blood gas ... were considered "the most important laboratory test for ... by Dr. John Severinghaus, inventor of the blood ...
... ,Contributing Editor , ,Positive patient identification (ID) is ... few years. Until recently, the costs associated with hardware ... or laboratory. Today there are multiple vendors with devices ... ease. Some systems are better for small facilities, while ...
Cached Medicine Technology:Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4Managing Preanalytical Processes for Patient Safety 2Managing Preanalytical Processes for Patient Safety 3Managing Preanalytical Processes for Patient Safety 4
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Rebuild Schools and Clinics, LOS ANGELES, May 14 ... relief agency,today announced that it is responding with aid ... earthquake has mobilized relief agencies from,around the world and ... the call., The Chinese Army is taking the ...
... Offers Tips to Help Make Healthy Choices on the ... Swimsuit season is right around the,corner and for many ... though, cutting back on calories and finding time to ... CareerBuilder.com survey reports,that 45 percent of workers have gained ...
... by Johns Hopkins doctors has fine-tuned the dosage and ... patients with strokes caused by bleeding within the brain. ... Stroke Conference in Nice, France, has been shown to ... typically lethal subset of stroke. , "We,ve gone from ...
... children can be picky eaters,spooked by strong flavors or ... the taste of the pickiest eaters. But just because ... family can,t,enjoy something with more zip. To help parents ... without spending all night in the kitchen,Mealtime.org has devised ...
... Stable Treatment for Hemophilia With ... Patients, PRINCETON, N.J., May 13 Novo ... Administration (FDA) has approved,NovoSeven(R) RT (Coagulation Factor VIIa ... recombinant product available,for the treatment of bleeding episodes ...
... Ill., May 13 Z Trim Holdings, Inc.,(Amex: ... statements,for the fiscal year ended December 31, 2007 contained ... accounting,firm, Blackman Kallick LLP. This announcement is being made ... which requires separate disclosure,of receipt of an audit opinion ...
Cached Medicine News:Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 2Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 3Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 4Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Personalized Plates for Picky Palates: Moms can Satisfy all With One Recipe, Four Ways 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 3Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 4Health News:Z Trim Holdings, Inc. Audit Report Contains 'Going Concern' Qualification 2
... lightweight self-adhesive insulin pod that you fill with ... up to three days and then replace. The ... your body through a small flexible tube (called ... into its wireless companion, the Personal Diabetes Manager. ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... Radiancys premium product for acne, ... clinical results on a scalable multi-application ... fight against acne, XtremeClear works fast, ... first few treatments. Uncompromising safety in ...
Medicine Products: